BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesEarnings

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated

Open original release

Related news

NBIXNeurocrine Biosciences2026-04-14 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

HRMYHarmony Biosciences2026-04-23 12:05 EST

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

BCLIBrainstorm Cell Therapeutics Inc.2026-05-15 20:05 EST

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

IKTInhibikase Therapeutics2026-05-12 20:01 EST

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

ABOSAcumen Pharmaceuticals2026-05-12 11:00 EST

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ANNXAnnexon, Inc.2026-05-07 20:01 EST

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

View all latest news

Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, neurology, and endocrinology. Its commercial and development work centers on disorders with clear unmet need and durable treatment demand.

Recent company news

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

NBIXNeurocrine Biosciences2026-05-18 20:05 EST

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

NBIXNeurocrine Biosciences2026-05-06 12:30 EST

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Stock data

Close
176.41 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States